BCX-34: a novel T-cell selective immunosuppressant: purine nucleoside phosphorylase (PNP) inhibitor.
We evaluated the efficacy of a new purine nucleoside phosphorylase inhibitor, BCX-34, as an immunosuppressive agent. BCX-34 showed a complete inhibitory effect on the proliferation of T-cells in an in vitro system, whereas no influence was observed in B-cell lines. In addition, it was revealed that this inhibitory effect was not due to the suppression of interleukin-2 production. Therefore, BCX-34 might be a potentially useful drug that can be used in combination, not competition, with cyclosporine A and FK506.
Wada
Y
Y
First Department of Surgery, Sapporo Medical University, School of Medicine, Japan.
Yagihashi
A
A
Terasawa
K
K
Miyao
N
N
Hirata
K
K
Cicciarelli
J
J
Iwaki
Y
Y
D000818:Animals; D001402:B-Lymphocytes / Q000166:cytology / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D016572:Cyclosporine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004357:Drug Synergism; D006147:Guanine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D007376:Interleukin-2 / Q000378:metabolism; D019169:Jurkat Cells / Q000166:cytology / Q000187:drug effects; D015458:Leukemia, T-Cell / Q000473:pathology; D051379:Mice; D011683:Purine-Nucleoside Phosphorylase / Q000037:antagonists & inhibitors*; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D016559:Tacrolimus / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
D007166:Immunosuppressive Agents; D007376:Interleukin-2; D006147:Guanine; C104194:peldesine; D016572:Cyclosporine; D011683:Purine-Nucleoside Phosphorylase; D016559:Tacrolimus